ArticleEuropean spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society2026
Comparative analysis of pelvic/sacral versus vertebral chordomas in the US from 2000 to 2020.
Article in European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Risk factors for postoperative recurrence of sacral chordoma: an eleven-year single-centre retrospective study.International orthopaedics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeChordomas are rare tumors of the axial skeleton, with 55% of cases affecting the pelvis/sacrum and 10% affecting the vertebrae of the spine. We seek to provide a comparative analysis of demographic, disease, and treatment variables between these two disease sites.
methodsPatients with chordomas were identified via the Surveillance, Epidemiology, and End Results (SEER) Program. Inclusion criteria were malignant chordoma (ICD-O-3 codes 9370/3-9372/3) limited to the pelvis, sacrum, or vertebrae of the spine (PSV). Fisher's Exact, Cox regression, and Kaplan-Meier survival analysis was conducted to assess variation between PSV disease sites.
resultsEight-hundred-ninety-six patients diagnosed with chordomas of the PSV were identified. Patients with pelvic/sacral chordomas were more likely to be older (p < 0.001), proportionally more non-White (16.7% vs. 9.5%; p = 0.010), come from urban counties (p = 0.042), and have more advanced disease (p < 0.001) compared to those with vertebral chordomas. Patients with pelvic/sacral chordomas were also less likely to undergo radiotherapy (p < 0.001) but were more likely to undergo gross total resection (p < 0.001). Five-year overall survival (5y OS) was 75.4% [71.71-79.16] for pelvic/sacral versus 77.0% [72.81-81.24] for vertebral chordomas, with no difference on Kaplan-Meier analysis (p = 0.729); however, Cox regression demonstrated vertebral chordomas worsened survival (hazard ratio 1.63, p = 0.004). Disease histology was associated with variation in 5y OS (p < 0.001); treatment with surgery was associated with increased 5y OS (p < 0.001 for both disease sites).
conclusionPrimary tumor site was independently associated with survival on multivariable analysis, despite no difference in unadjusted 5y OS between pelvic/sacral and vertebral chordomas. Significant differences in demographic, disease, and treatment characteristics were observed between groups, indicating that underlying factors may contribute to prognosis in unadjusted survival comparisons. Further investigation into the impact of disease histology and treatment modalities is warranted.
Indexed as
Identifiers
42321423What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.